1. Home
  2. SPRO vs LFCR Comparison

SPRO vs LFCR Comparison

Compare SPRO & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.70

Market Cap

135.5M

Sector

Health Care

ML Signal

HOLD

Logo Lifecore Biomedical Inc.

LFCR

Lifecore Biomedical Inc.

HOLD

Current Price

$4.60

Market Cap

143.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
LFCR
Founded
2013
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
135.5M
143.9M
IPO Year
2017
1996

Fundamental Metrics

Financial Performance
Metric
SPRO
LFCR
Price
$2.70
$4.60
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$6.00
AVG Volume (30 Days)
408.3K
189.6K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
111.81
N/A
EPS
N/A
N/A
Revenue
$66,802,000.00
$557,559,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$300.00
$5.04
P/E Ratio
$16.23
N/A
Revenue Growth
39.24
6.36
52 Week Low
$0.65
$3.63
52 Week High
$3.09
$8.98

Technical Indicators

Market Signals
Indicator
SPRO
LFCR
Relative Strength Index (RSI) 56.63 40.81
Support Level $2.15 $3.63
Resistance Level $2.70 $5.45
Average True Range (ATR) 0.14 0.27
MACD -0.01 -0.05
Stochastic Oscillator 85.53 20.50

Price Performance

Historical Comparison
SPRO
LFCR

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About LFCR Lifecore Biomedical Inc.

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.

Share on Social Networks: